

## Life Sciences

Since our founding five decades ago, we have been an active player in the life sciences industry, handling complex transactions on a national and international platform. Because of the complexities of life sciences transactions, we have established an experienced interdisciplinary team to provide a full range of legal services focusing on all aspects of these transactions. This allows us to offer a wide range of integrated services designed to handle your important transactions in an expeditious and cost-effective manner.

Our industry knowledge is the result of years of accumulated legal and business experience and expertise. Our clients include a number of the largest pharmaceutical companies, medical device manufacturers, biotechnology companies, scientific and research organizations, and related life sciences companies in New Jersey and the rest of the United States, as well as international life sciences companies. We also represent start-ups and spinoffs, including their organization, funding and development collaborations, as they grow and take new products to the marketplace.

We understand the fast-paced life sciences industry and know that you need answers to your legal questions in a timely manner. We are responsive and provide the necessary guidance that you need to continue with your business goals. Client service is our number one priority.

### Areas of Expertise

- Mergers and Acquisitions
- Licensing Arrangements
- Strategic Alliance and Collaborations
- Joint Ventures
- Manufacturing, Supply and Distribution Agreements
- Public and Private Financing
- Technology Transfers
- Intellectual Property
- Litigation
- Employment Law
- Real Estate
- Regulatory
- Tax

### Representative Matters

---

- Representation of an international pharmaceutical company and leader in the generics industry

# Sills Cummis & Gross P.C.

in connection with the acquisition of worldwide rights to a therapeutic treatment for metastatic prostate cancer.

- Representation of a publicly-traded pharmaceutical company in the purchase of a business focused on marketing and sale of branded pharmaceuticals, including a lead product detailed primarily to endocrinologists and high prescribing primary care physicians.
- Representation of an Italian multinational company and global in vitro diagnostics leader in the acquisition of the Focus Diagnostics' immunodiagnostic and molecular diagnostic products business from Quest Diagnostics (NYSE:DGX) for \$300 million.
- Representation of the owner/operator of integrated senior health care campuses in several states in the \$1.25 billion sale of its health care facility portfolio to a joint venture comprised of two publicly traded REITs.
- Representation of a pharmaceutical company in the acquisition of the rights to three branded women's health products from Upsher-Smith Laboratories, Inc.
- Representation of a health care fund in an investment in Aeglea Biotherapeutics, Inc.
- Representation of a health care technology company in the sale of substantially all the assets of its pharmaceutical chemistry development and manufacturing business to a subsidiary of McKesson Corporation.
- Representation of a company developing products to diagnose and treat dry and wet age-related macular degeneration (AMD) and other chronic diseases involving the alternative complement system in its start-up financing.
- Representation of a developer, manufacturer and marketer of pharmaceutical products in the sale of its generic prescription caffeine suppository used for the treatment of migraines, to Crealta Pharmaceuticals LLC, a specialty pharma company formed by GTCR, a leading private equity firm.
- Representation of a biotechnology company in an exclusive worldwide license agreement with Bayer AS for the development and commercialization of therapeutic antibodies containing the company's prostate specific membrane antigen (PSMA) antibody technology.
- Representation of a bone reconstruction company in its spin-out from Columbia University, and its Series A Convertible Note Financing and exclusive worldwide license agreement with Columbia Technology Ventures.
- Representation of a biotechnology company in an exclusive worldwide license agreement with Johns Hopkins University for 18F DCFPyL.
- Representation of new venture capital-backed companies in their organization and the licensing of platform technology from Yale University, Columbia University and other universities.